Olpasiran
Olpasiran (AMG890) is an experimental antisense therapy designed to lower the level of lipoprotein(a), which is believed to be a causal factor in the development of cardiovascular disease. The drug is developed by Amgen.[1][2]
References
- .
- ISSN 1546-170X.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |